Add To Watchlist
Share URL
About The Company
CEO
Mr. David A. Ricks
Market Cap
690.55 Billion USD
Sector
Healthcare
Website
https://www.lilly.comLast Update
2/22/2024, 12:00:00 PM
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide.
Read More
Overview
Value
4
Growth
44
Health
46
Management
56
Analyst Opinion
94
Total
49
All Scores Out Of 100
Best Features
- Has a history of share buybacks
- Low risk of bankruptcy
- Liked by analysts
- Has strong dividend growth
Risk Factors
- Overvalued on cashflow basis
- Earnings have declined recently
- Income is not covering expenditure and investment
- Has a high level of debt
- No margin of safety at their current market price
- Disliked by Twitter users
- Price-to-earnings ratio of 139.1 is higher than the market average (19.6x)
- High preportion of income is paid as dividend
Market Peers
LLY
Key Figures
PE Ratio (TTM)
139.09
Margin Of Safety (DCF)
-74.34%
Revenue Growth (5 Year Average)
8.65%
Ratings Consensus
Strong Buy
Share Buybacks
3.04%
Dividend Yeild (TTM)
0.54%
Valuation
Value Score
4
- ✘ Estimated intrinsic-value of 203.30 USD is lower than current price ( 726.31 USD)
- ✘ Price-to-earnings ratio of 139.1 is higher than the market average (19.6x)
- ✘ Free-cashflow-yeild of -0.42% is worse than the market average (4.7%)
- ✘ Margin-of-safety of -74.34% is worse than the market average (17.95%)
Desired Margin Of Safety
0%
▼
Tip: Set your desired Margin Of Safety
Free Cash Flow Type
Annual Cashflow Growth
0%
Discount Rate
0%
Buy Target: < 185.3 USD ✘
Current Price: 792.3 USD
How Does This Work?
Show Advanced Options
This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.
Price/Earnings
139.09x
Free Cashflow Yeild
-0.42%
PE/Earnings Growth
20.25
Price/Book
69.29x
Growth
Growth Score
44
- ✔ Revenue growth has improved this yeara
- ✔ 5 Year Average Cashflow growth of 16.89% is higher than the market average (12.35%)
- ✘ 5 Year Average Revenue growth of 8.65% is lower than the market average (10.97%)
- ✘ 5 Year Average Earnings growth of 0.92% is lower than the market average (14.48%)
- ✘ Earnings growth has slowed this year
- ✘ Free Cashflow growth has slowed this year
Revenue Growth
8.65%
Earnings Growth
0.92%
Cashflow Growth
16.89%
Health
Health Score
46
Altman Z Score
9.30
Piostroski Score
5.00
Debt/Equity
1.52x
Current Assets/Liabilities
1.05x
Free Cashflow/Total Debt
0.32x
Debt/Capital
0.90x
Dividend
Secure Dividend Score
39
- ✘ At risk of being unsafe
- ✔ Long term dividend payout ratio of -136.37% is considered good
- ✔ Dividends have shown growth over the last 5 years
- ✘ Dividend yeild of 0.54% is less than the market average (1.85%)
- ✘ Payout ratio (TTM) of 77.65% is higher than the average (40%)
- ✘ Spending a higher percentage of their income on dividends than last 5 years
Dividend Yeild
0.54%
Dividend Growth
14.91%
Payout Ratio (Earnings)
77.65%
Payout Ratio (Cashflow)
-129.10%
Management
Management Score
56
- ✔ Has a history of returning value to shareholders through stock buybacks
- ✔ Has returned higher dividends when earnings have risen
- ✔ Return-on-equity of 58.64% is higher than the market average (15%)
- ✔ Return-on-capital-employed of 14.38% is higher than the market average (10%)
- ✘ Has repurchased shares when overvalued
Average Buybacks/Dilution
3.04%
Recent Buybacks/Dilution
5.37%
5 Year Price Volitility
45.79%
Return On Assets
12.62%
Return On Capital Employed
14.38%
Return On Equity
58.64%
Return On Free Cashflow
N/A
Return On Investments
204.97%
Analysts
Analyst Opinion
94
- ✔ Ratings consensus is Strong Buy
SEC Filings
Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.
Other Information
Company Name
Eli Lilly and Company
Currency
USD
Beta
0.357923
Vol Avg
3011550
Ceo
Mr. David A. Ricks
Cik
0000059478
Cusip
532457108
Exchange
New York Stock Exchange
Full Time Employees
39000
Industry
Drug Manufacturers—General
Sector
Healthcare
Ipo Date
1972-06-01
Address
Lilly Corporate Center
City
Indianapolis
State
IN
Country
US
Zip
46285
Phone
317 276 2000
Analysis Last Updated
2/22/2024, 12:00:00 PM
All financial data provided by FMP
Social Sentiment
Social Sentiment Score
0
Twitter Sentiment
N/A
Stocktwits Sentiment
N/A